Geneva Capital Management LLC Decreases Holdings in Azenta, Inc. (NASDAQ:AZTA)

Geneva Capital Management LLC trimmed its stake in Azenta, Inc. (NASDAQ:AZTA) by 0.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 510,329 shares of the company’s stock after selling 1,594 shares during the quarter. Geneva Capital Management LLC owned approximately 0.92% of Azenta worth $30,763,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Park Avenue Securities LLC grew its holdings in Azenta by 1.6% during the first quarter. Park Avenue Securities LLC now owns 12,181 shares of the company’s stock valued at $734,000 after purchasing an additional 192 shares during the period. Retirement Systems of Alabama lifted its holdings in Azenta by 0.3% during the fourth quarter. Retirement Systems of Alabama now owns 75,339 shares of the company’s stock valued at $4,908,000 after purchasing an additional 230 shares during the last quarter. Headlands Technologies LLC boosted its position in Azenta by 35.6% during the fourth quarter. Headlands Technologies LLC now owns 883 shares of the company’s stock worth $58,000 after purchasing an additional 232 shares during the period. Raymond James & Associates increased its stake in shares of Azenta by 0.3% in the fourth quarter. Raymond James & Associates now owns 96,126 shares of the company’s stock worth $6,262,000 after purchasing an additional 285 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in shares of Azenta by 9.3% in the first quarter. Janney Montgomery Scott LLC now owns 5,167 shares of the company’s stock valued at $311,000 after purchasing an additional 438 shares during the period. 99.08% of the stock is owned by institutional investors.

Azenta Price Performance

Azenta stock traded up $2.29 during trading hours on Thursday, reaching $52.82. The company had a trading volume of 734,747 shares, compared to its average volume of 468,197. Azenta, Inc. has a 12-month low of $43.43 and a 12-month high of $69.16. The company has a 50-day moving average price of $52.75 and a 200 day moving average price of $58.57. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of -19.48 and a beta of 1.51.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. Azenta had a negative net margin of 23.12% and a positive return on equity of 0.81%. The firm had revenue of $159.13 million during the quarter, compared to the consensus estimate of $159.89 million. During the same period in the prior year, the firm posted ($0.06) earnings per share. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. As a group, research analysts expect that Azenta, Inc. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on AZTA shares. Needham & Company LLC reduced their price objective on shares of Azenta from $75.00 to $69.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Evercore ISI lifted their price target on Azenta from $52.00 to $53.00 and gave the company an “in-line” rating in a research report on Tuesday, July 2nd. Finally, Jefferies Financial Group began coverage on Azenta in a report on Thursday, April 4th. They set a “hold” rating and a $64.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $67.00.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.